针对NRAS 突变型黑色素瘤的靶向治疗仍然具有挑战性。
War against NRAS-Mutant Melanoma Using Targeted Therapies Remains Challenging.
机构信息
Division of Medical Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
出版信息
Clin Cancer Res. 2022 Jul 15;28(14):2977-2979. doi: 10.1158/1078-0432.CCR-22-1256.
Abstract
In the search for targeting MAPK plus other pathways in NRAS-mutant melanoma, a phase Ib/II trial tested binimetinib plus ribociclib in metastatic melanoma. The response rate in the phase II trial was 19.5%, and the median progression-free survival was 3.7 months. See related article by Schuler et al., p. 3002.
摘要
在寻找针对 NRAS 突变黑色素瘤的 MAPK 加其他途径的方法时，一项 Ib/II 期试验测试了 binimetinib 加 ribociclib 在转移性黑色素瘤中的疗效。II 期试验的缓解率为 19.5%，中位无进展生存期为 3.7 个月。见 Schuler 等人的相关文章，第 3002 页。
Zotero 插件